The distribution of peanut agglutinin (PNA) receptors, nonspecific cross-reacting antigen (NCA) molecule and 3-fucosyl-N-acetyllactosamine (FAL) in myeloid leukemic cells isolated by density gradient centrifugation was compared using immunofluorescence test (IF). Patients with acute myelocytic leukemias (AML) type M2 and M5 showed low percentage of NCA+ and PNA+ cells. In chronic and acute phase of chronic myelocytic leukemias (CML) the number of NCA containing cells increased and the amount of PNA-binding cells decreased as more mature granulocytic fractions were isolated on Ficoll--Uropoline density gradient. In patients with myeloblastic crisis of CML (CML-BC) the number of cells expressing FAL structure did not change in relation to maturation stage of myeloid cells. Our results revealed that the expression of various markers could change in a different way during the differentiation of cells from myeloblasts to mature granulocytes.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
MLL-AF4 upregulates 5-lipoxygenase expression in t(4;11) leukemia cells via the ALOX5 core promoter.
Front Pharmacol
January 2025
Institute of Pharmaceutical Chemistry, Goethe University, Frankfurt, Germany.
5-Lipoxygenase (5-LO), encoded by the gene , is implicated in several pathologies. As key enzyme in leukotriene biosynthesis, 5-LO plays a central role in inflammatory diseases, but the 5-LO pathway has also been linked to development of certain hematological and solid tumor malignancies. Of note, previous studies have shown that the leukemogenic fusion protein MLL-AF4 strongly increases gene promoter activity.
View Article and Find Full Text PDFAllogeneic DNT cell therapy synergizes with T cells to promote anti-leukemic activities while suppressing GvHD.
J Exp Clin Cancer Res
January 2025
Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a second-line treatment with curative potential for leukemia patients. However, the prognosis of allo-HSCT patients with disease relapse or graft-versus-host disease (GvHD) is poor. CD4 or CD8 conventional T (Tconv) cells are critically involved in mediating anti-leukemic immune responses to prevent relapse and detrimental GvHD.
View Article and Find Full Text PDFThin Layer Chromatography Goes Ultrasmall to Assay Sphingosine Kinase Activation in Single Primary Leukemic Cells.
Anal Chem
January 2025
Department of Bioengineering, University of Washington, SeattleWashington98195, United States.
Cell-to-cell heterogeneity in lipid signaling underlies variations in response and recurrence for many cancers, including leukemias. A highly parallel, miniaturized thin-layer chromatographic platform capable of assaying single cells was developed. Ultrasmall volumes (50 pL) of standard fluorescent lipids were separated with excellent repeatability, reproducibility, and limits of detection.
View Article and Find Full Text PDFLeukemic Hypopyon in Refractory Acute Myeloid Leukemia.
Indian J Pediatr
January 2025
Pediatric Hematology-Oncology Unit, Department of Pediatrics, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Identification and validation of BATF as a prognostic biomarker and regulator of immune cell infiltration in acute myeloid leukemia.
Front Immunol
January 2025
Department of Hematology, Qilu Hospital of Shandong University, Jinan, China.
Background: Basic leucine zipper ATF-like transcription factor (BATF) is a nuclear basic leucine zipper protein affiliated with the AP-1/ATF superfamily. Previous research has confirmed that BATF expression plays a significant role in the tumour microenvironment. However, the associations between BATF expression and prognoses in acute myeloid leukaemia (AML) patients and their immunological effects remain unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!